JP5799161B2 - 酸化鉄ナノ粒子に基づくリンパ系造影用mri造影剤およびこれを用いてリンパ節を造影する方法 - Google Patents
酸化鉄ナノ粒子に基づくリンパ系造影用mri造影剤およびこれを用いてリンパ節を造影する方法 Download PDFInfo
- Publication number
- JP5799161B2 JP5799161B2 JP2014503614A JP2014503614A JP5799161B2 JP 5799161 B2 JP5799161 B2 JP 5799161B2 JP 2014503614 A JP2014503614 A JP 2014503614A JP 2014503614 A JP2014503614 A JP 2014503614A JP 5799161 B2 JP5799161 B2 JP 5799161B2
- Authority
- JP
- Japan
- Prior art keywords
- dihydroxyphenylalanine
- lymph node
- iron oxide
- polyethylene glycol
- polyethyleneimine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
- A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Description
Claims (9)
- 水性溶媒に親和性を有するポリエチレングリコール系生体適合性高分子を接合した分岐ポリエチレンイミン、およびナノ粒子の表面に親和性を有するポリ3,4−ジヒドロキシフェニルアラニン(PDOPA)を含むポリエチレンイミン‐グラフト‐(ポリエチレングリコール;ポリ3,4−ジヒドロキシフェニルアラニン)によって水性溶媒中に分散および安定化した酸化鉄ナノ粒子を含み、前記ポリ3,4−ジヒドロキシフェニルアラニン(PDOPA)は、L‐DOPA(L−3,4−ジヒドロキシフェニルアラニン)のN‐カルボキシ無水物から合成したL‐PDOPA、D‐DOPA(D−3,4−ジヒドロキシフェニルアラニン)のN‐カルボキシ無水物から合成したD‐PDOPA、およびL,D‐DOPAのN‐カルボキシ無水物から合成したL,D‐PDOPAから選択されることを特徴とする、リンパ節造影剤。
- 前記酸化鉄ナノ粒子は、直径が1〜25nmであることを特徴とする、請求項1に記載のリンパ節造影剤。
- 前記水性溶媒中に分散した酸化鉄ナノ粒子は、流体力学的直径が3〜100nmであることを特徴とする、請求項1又は2に記載のリンパ節造影剤。
- 前記ポリエチレングリコールは、数平均分子量が300〜50,000であり、その一端にヒドロキシル基またはカルボキシル基を有していることを特徴とする、請求項1から3の何れか一項に記載のリンパ節造影剤。
- 前記分岐ポリエチレンイミンは、数平均分子量が100〜10,100であることを特徴とする、請求項1から4の何れか一項に記載のリンパ節造影剤。
- 前記ポリエチレンイミン‐グラフト‐(ポリエチレングリコール;ポリ3,4−ジヒドロキシフェニルアラニン)は、
下記構造(A)で表されるポリエチレングリコールユニットと、
分岐ポリエチレンイミンユニットと、
下記構造(C)で表されるポリ3,4−ジヒドロキシフェニルアラニンユニットと、を含むことを特徴とする、請求項1から5の何れか一項に記載のリンパ節造影剤。
(A)
[aは、2〜1200の範囲である。]
(C)
[dの範囲は、1〜100である。] - 投与前のリンパ節のMRIシグナルと、投与後のリンパ節のMRIシグナルの強度変化または強度差を用いてリンパ節を造影するために用いることを特徴とする、請求項1から6の何れか一項に記載のリンパ節造影剤。
- 静脈注射によって投与されることを特徴とする、請求項1から7の何れか一項に記載のリンパ節造影剤。
- 前記リンパ節のMRIシグナルの強度変化は、T2シグナル強度の変化を基準とする、請求項7又は8に記載のリンパ節造影剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110060438A KR101721570B1 (ko) | 2011-06-22 | 2011-06-22 | 산화철 나노입자 기반 림프절 이미징용 mri 조영제 및 이를 이용하여 림프절을 조영하는 방법 |
KR10-2011-0060438 | 2011-06-22 | ||
PCT/KR2012/004861 WO2012177039A2 (en) | 2011-06-22 | 2012-06-20 | Mri contrast agent for lymphography based on iron oxide nanoparticles and method for imaging lymph node using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014514301A JP2014514301A (ja) | 2014-06-19 |
JP5799161B2 true JP5799161B2 (ja) | 2015-10-21 |
Family
ID=47423073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014503614A Active JP5799161B2 (ja) | 2011-06-22 | 2012-06-20 | 酸化鉄ナノ粒子に基づくリンパ系造影用mri造影剤およびこれを用いてリンパ節を造影する方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8906346B2 (ja) |
EP (1) | EP2723392B1 (ja) |
JP (1) | JP5799161B2 (ja) |
KR (1) | KR101721570B1 (ja) |
CN (1) | CN103458932B (ja) |
AU (1) | AU2012274234A1 (ja) |
BR (1) | BR112013023812A2 (ja) |
CA (1) | CA2827752C (ja) |
MX (1) | MX2013009212A (ja) |
WO (1) | WO2012177039A2 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101685646B1 (ko) * | 2010-12-29 | 2016-12-13 | 한화케미칼 주식회사 | 홍합 접착단백질 모방을 통한 나노입자를 수계 매질에 분산시키는 생체적합성 분산 안정화제 |
DK3092012T3 (da) * | 2014-01-07 | 2019-09-02 | Colorobbia Italiana Spa | Magnetiske nanopartikler, der er funktionaliseret med catechol, fremstilling og anvendelse deraf |
KR101510835B1 (ko) * | 2014-01-09 | 2015-04-10 | 원광대학교산학협력단 | 홍합 접착 단백질 유래 키토산올리고당 리간드 및 이를 포함하는 조영제 |
KR101508600B1 (ko) * | 2014-01-09 | 2015-04-07 | 원광대학교산학협력단 | 생체유래 키토올리고당 리간드 및 이를 포함하는 조영제 |
CN104258421B (zh) * | 2014-09-12 | 2016-09-21 | 温州大学 | 一种贵金属/顺磁金属复合纳米粒子及其应用 |
KR101720046B1 (ko) * | 2014-09-26 | 2017-03-29 | 서울대학교산학협력단 | 광역학 치료용 자기조립형 약학 조성물 |
KR101765335B1 (ko) * | 2014-09-26 | 2017-08-22 | 서울대학교산학협력단 | 암 세포 조영용 mri 조영제 조성물 |
KR101722503B1 (ko) * | 2015-03-13 | 2017-04-04 | 포항공과대학교 산학협력단 | 홍합 접착 단백질을 이용한 약물전달용 pH-반응성 나노입자 및 이의 제조방법 |
CN105400517B (zh) * | 2015-10-30 | 2018-03-13 | 玉林师范学院 | 检测镉离子的双功能磁性荧光探针制备方法及其应用 |
CN110496231B (zh) * | 2018-05-16 | 2020-09-18 | 浙江大学 | 一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用 |
EP3860342A4 (en) * | 2018-10-03 | 2022-08-03 | Prescient Pharma LLC | COMPOSITIONS AND METHODS FOR ISOLATING CIRCULATING CELLS |
WO2023040037A1 (zh) * | 2021-09-18 | 2023-03-23 | 中国科学院大学附属肿瘤医院 | 氧化铁纳米粒子在制备甲状旁腺和/或淋巴结显影剂中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6323670A (ja) * | 1986-04-25 | 1988-01-30 | バイオ−ポリマ−ズ インコ−ポレ−テツド | 接着・被覆組成物とその使用方法 |
US4908404A (en) * | 1988-08-22 | 1990-03-13 | Biopolymers, Inc. | Synthetic amino acid-and/or peptide-containing graft copolymers |
JPH10120597A (ja) * | 1996-10-22 | 1998-05-12 | Eiken Chem Co Ltd | リンパ節高集積性コロイド粒子 |
US20020012698A1 (en) * | 1999-09-01 | 2002-01-31 | Edmund Bauerlein | Magnetosomes, method for making and using |
WO2006073419A2 (en) * | 2004-04-01 | 2006-07-13 | Gang Zheng | Lipoprotein nanoplatforms |
US20090280063A1 (en) * | 2008-05-09 | 2009-11-12 | General Electric Company | Novel pei-peg graft copolymer coating of iron oxide nanoparticles for inflammation imaging |
EP2289553A1 (en) * | 2009-09-01 | 2011-03-02 | ETH Zurich | Dispersant stabilization of inorganic non-metallic particles |
JP2011079781A (ja) * | 2009-10-08 | 2011-04-21 | Keio Gijuku | センチネルリンパ節の造影剤ないし同定剤、温熱療法剤 |
KR101685646B1 (ko) * | 2010-12-29 | 2016-12-13 | 한화케미칼 주식회사 | 홍합 접착단백질 모방을 통한 나노입자를 수계 매질에 분산시키는 생체적합성 분산 안정화제 |
-
2011
- 2011-06-22 KR KR1020110060438A patent/KR101721570B1/ko active IP Right Grant
-
2012
- 2012-06-20 JP JP2014503614A patent/JP5799161B2/ja active Active
- 2012-06-20 US US14/000,301 patent/US8906346B2/en active Active
- 2012-06-20 WO PCT/KR2012/004861 patent/WO2012177039A2/en active Application Filing
- 2012-06-20 MX MX2013009212A patent/MX2013009212A/es not_active Application Discontinuation
- 2012-06-20 CA CA2827752A patent/CA2827752C/en not_active Expired - Fee Related
- 2012-06-20 EP EP12802287.8A patent/EP2723392B1/en active Active
- 2012-06-20 CN CN201280011330.XA patent/CN103458932B/zh active Active
- 2012-06-20 BR BR112013023812A patent/BR112013023812A2/pt not_active IP Right Cessation
- 2012-06-20 AU AU2012274234A patent/AU2012274234A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20140023594A1 (en) | 2014-01-23 |
KR101721570B1 (ko) | 2017-03-30 |
WO2012177039A2 (en) | 2012-12-27 |
US8906346B2 (en) | 2014-12-09 |
BR112013023812A2 (pt) | 2016-12-13 |
CA2827752A1 (en) | 2012-12-27 |
EP2723392A4 (en) | 2014-12-17 |
WO2012177039A3 (en) | 2013-04-04 |
MX2013009212A (es) | 2013-08-29 |
AU2012274234A1 (en) | 2013-08-22 |
EP2723392A2 (en) | 2014-04-30 |
KR20130008095A (ko) | 2013-01-22 |
CA2827752C (en) | 2016-05-17 |
CN103458932A (zh) | 2013-12-18 |
JP2014514301A (ja) | 2014-06-19 |
EP2723392B1 (en) | 2016-09-28 |
CN103458932B (zh) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5799161B2 (ja) | 酸化鉄ナノ粒子に基づくリンパ系造影用mri造影剤およびこれを用いてリンパ節を造影する方法 | |
US9169355B2 (en) | Biocompatible agent for dispersing nanoparticles into an aqueous medium using mussel adhesive protein-mimetic polymer | |
Bae et al. | Bioinspired synthesis and characterization of gadolinium-labeled magnetite nanoparticles for dual contrast T 1-and T 2-weighted magnetic resonance imaging | |
Maurizi et al. | Influence of surface charge and polymer coating on internalization and biodistribution of polyethylene glycol-modified iron oxide nanoparticles | |
Park et al. | Multi-modal transfection agent based on monodisperse magnetic nanoparticles for stem cell gene delivery and tracking | |
Wang et al. | Antifouling manganese oxide nanoparticles: synthesis, characterization, and applications for enhanced MR imaging of tumors | |
CN103143043B (zh) | 一种Fe3O4/Au复合纳米颗粒的制备方法 | |
US20120114564A1 (en) | Mri t1 contrasting agent comprising manganese oxide nanoparticle | |
TW201113040A (en) | Folic acid-mediated magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications | |
Xiao et al. | Superparamagnetic iron oxide nanoparticles stabilized with multidentate block copolymers for optimal vascular contrast in T 1-weighted magnetic resonance imaging | |
Yang et al. | Folate-conjugated cross-linked magnetic nanoparticles as potential magnetic resonance probes for in vivo cancer imaging | |
JP6425486B2 (ja) | 癌細胞の造影用mri造影剤組成物 | |
Nguyen et al. | Integration of iron oxide nanoparticles and polyaspartamide biopolymer for MRI image contrast enhancement and an efficient drug-delivery system in cancer therapy | |
Atrei et al. | Covalent hyaluronic-based coating of magnetite nanoparticles: Preparation, physicochemical and biological characterization | |
WO2014145573A1 (en) | Coated magnetic nanoparticles for imaging enhancement and drug delivery | |
KR101143257B1 (ko) | 만노스가 말단 수식된 고분자가 코팅된 자기공명 영상 조영제 및 그것의 제조 방법 | |
Shi | Superparamagnetic nanoparticles for magnetic resonance imaging (MRI) diagnosis | |
Danafar | New Insight about Biocompatibility and Biodegradability of Iron oxide Magnetic Nanoparticles: stereological and In VivoMRI Monitor | |
Hajdu | Preparation and in vitro for tumor specific targeted de | |
KR20140099357A (ko) | 초상자성 산화철을 포함한 자기공명영상 조영제 전달체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150202 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150810 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150824 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5799161 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |